Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) Tax Provisions (2022 - 2025)

Gyre Therapeutics (GYRE) has disclosed Tax Provisions for 7 consecutive years, with $901000.0 as the latest value for Q1 2025.

  • On a quarterly basis, Tax Provisions changed N/A to $901000.0 in Q1 2025 year-over-year; TTM through Mar 2025 was $11.7 million, a N/A change, with the full-year FY2024 number at $6.3 million, down 25.75% from a year prior.
  • Tax Provisions was $901000.0 for Q1 2025 at Gyre Therapeutics, down from $1.2 million in the prior quarter.
  • In the past five years, Tax Provisions ranged from a high of $8.5 million in Q4 2023 to a low of -$2.0 million in Q3 2023.
  • A 4-year average of $2.2 million and a median of $1.1 million in 2024 define the central range for Tax Provisions.
  • Biggest YoY gain for Tax Provisions was 152.65% in 2024; the steepest drop was 85.82% in 2024.
  • Gyre Therapeutics' Tax Provisions stood at $6.0 million in 2022, then skyrocketed by 41.93% to $8.5 million in 2023, then crashed by 85.82% to $1.2 million in 2024, then fell by 25.23% to $901000.0 in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Tax Provisions are $901000.0 (Q1 2025), $1.2 million (Q4 2024), and $1.1 million (Q3 2024).